Holen Sie sich die Stockscreener-App
30.77
0.75%
0.23
Vorhandelsmarkt:
31.07
0.30
+0.97%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$30.54
Offen:
$30.15
24-Stunden-Volumen:
458.64K
Relative Volume:
0.86
Marktkapitalisierung:
$1.14B
Einnahmen:
$154.15M
Nettoeinkommen (Verlust:
$-33.58M
KGV:
-32.05
EPS:
-0.96
Netto-Cashflow:
$-20.74M
1W Leistung:
-2.96%
1M Leistung:
+9.46%
6M Leistung:
-8.29%
1J Leistung:
+46.18%
1-Tages-Spanne:
$29.78
$30.86
1-Wochen-Bereich:
$29.78
$32.46
52-Wochen-Spanne:
$20.36
$59.23
Harrow Inc Stock (HROW) Company Profile
Firmenname
Harrow Inc
Sektor
Telefon
615.733.4731
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Vergleichen Sie HROW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
30.77 | 1.14B | 154.15M | -33.58M | -20.74M | -0.96 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-12 | Eingeleitet | BTIG Research | Buy |
| 2025-06-10 | Eingeleitet | William Blair | Outperform |
| 2025-02-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-04 | Bestätigt | B. Riley Securities | Buy |
| 2024-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2022-09-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-09-24 | Eingeleitet | Aegis Capital | Buy |
| 2021-07-02 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Harrow Inc Aktie (HROW) Neueste Nachrichten
HROW to Participate in Lake Street's Virtual Meeting on June 24 - GuruFocus
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications | HROW Stock News - GuruFocus
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire
Opaleye Management Inc. Adjusts Holdings in Harrow Inc. - GuruFocus
Harrow wins new Outperform at William Blair after licensing deal for pain drug - MSN
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options - The Globe and Mail
BTIG Initiates Harrow at Buy With $62 Price Target - MarketScreener
BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook - GuruFocus
Harrow Inc. sees $923,827 in stock sales by major shareholder - Investing.com South Africa
BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook | HROW Stock News - GuruFocus
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy - Benzinga
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options - The Globe and Mail
Harrow acquires U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals - MSN
Harrow (HROW) Gains Coverage with Outperform Rating Following Licensing Deal - GuruFocus
Harrow stock wins William Blair's new Outperform (HROW:NASDAQ) - Seeking Alpha
Assessing Harrow: Insights From 4 Financial Analysts - Benzinga
Lake Street Remains a Buy on Harrow Health (HROW) - The Globe and Mail
William Blair Initiates Coverage on Harrow (HROW) with Outperfor - GuruFocus
William Blair Initiates Coverage on Harrow With Outperform Rating - marketscreener.com
William Blair Initiates Outperform Rating for Harrow (HROW) | HR - GuruFocus
William Blair Initiates Outperform Rating for Harrow (HROW) | HROW Stock News - GuruFocus
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - mx.advfn.com
Harrow (HROW) Secures Exclusive U.S. Rights for New Ophthalmic S - GuruFocus
Harrow (HROW) Secures U.S. Rights to BYQLOVI - GuruFocus
Harrow Acquires US Commercial Rights for Byqlovi From Formosa Pharmaceuticals - marketscreener.com
Harrow Acquires U.S. Commercial Rights To Byqlovi(TM) From Formosa Pharmaceuticals - marketscreener.com
HROW Signs Licensing Agreement for Exclusive U.S. Rights to Byqlovi 0.05% | HROW Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 29,262 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Down 5.39% on Jun 5 - GuruFocus
Bank of America Corp DE Trims Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Millennium Management LLC Sells 101,671 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
B. Riley Issues Pessimistic Forecast for Harrow Earnings - Defense World
Insiders Favor Harrow And 2 Other Leading Growth Companies - Yahoo Finance
Harrow Inc (HROW) Shares Up 4.04% on May 30 - GuruFocus
Obituary for Douglas "Doug" A. Harrow - Schaffer Funeral Home, Inc.
Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (HROW) Stock Price Down 3.78% on May 22 - GuruFocus
Deutsche Bank AG Has $3.63 Million Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
The Manufacturers Life Insurance Company Has $372,000 Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Stock Price Up 8.35% on May 16 - GuruFocus
Harrow Inc.: Opaleye management sells $150,055 in stock - Investing.com Australia
Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com India
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey
Harrow to Present at Two Investor Conferences in May - Business Wire
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga
Harrow Health, Inc. (NASDAQ:HROW) Q1 2025 Earnings Call Transcript - Insider Monkey
Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus
HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus
Price T Rowe Associates Inc. MD Buys 1,428 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow (NASDAQ:HROW) Price Target Raised to $60.00 at HC Wainwright - Defense World
Where Harrow Stands With Analysts - Benzinga
Finanzdaten der Harrow Inc-Aktie (HROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harrow Inc-Aktie (HROW) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
| SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
| BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
29.64 |
5,000 |
148,200 |
145,000 |
1.05%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):